文献速递冠心病

双靶点心脏再生:Nfyb/Nr3c1 联合干预促进心肌梗死后心肌细胞胞质分裂

Dual-Target Cardiac Regeneration: Controllable Nfyb/Nr3c1 Cointervention Spurs Cardiomyocyte Cytokinesis After Myocardial Infarction.
PubMed 文献 · Circulation · 2026-08-25

该研究利用多种心肌再生模型和跨物种转录组分析,解析心肌细胞增殖的调控网络,发现 Nfyb 为增殖激活因子、Nr3c1 为增殖抑制因子。通过药物诱导 Nfyb 过表达联合 CRISPR 删除 Nr3c1 的双重干预,可协同促进心肌细胞新生。在心肌梗死小鼠和人工程化心肌组织中证实该策略可改善心脏修复。

要点

  • Nfyb 过表达促进心肌细胞增殖并改善心梗后心脏修复
  • Nr3c1 抑制可促进心肌细胞增殖、改善心功能并减少梗死面积
  • Nfyb/Nr3c1 联合干预协同促进新生心肌细胞形成

核心结论

  • Nfyb/Nr3c1 联合干预可诱导并调控损伤后心脏再生,是一种潜在的新治疗策略

研究设计与样本

  • 利用 5 种再生模型转录组数据,包括 Aurkb-tdTomato 胞质分裂报告小鼠和 Myh6-MerCreMer;MADM 小鼠
  • 采用跨物种比较分析探索心肌细胞增殖调控网络
  • 使用 MADM 小鼠通过量化胞质分裂后新生心肌细胞和克隆簇评估心脏再生

主要发现

  • 多模型整合分析揭示心肌细胞增殖存在双重调控系统
  • Nfyb 被鉴定为心肌细胞增殖激活因子,Nr3c1 为抑制因子
  • Nfyb 过表达通过驱动细胞周期基因转录促进心肌细胞增殖和心梗后心脏修复
  • Nr3c1 抑制促进心肌细胞增殖、改善心功能并减少梗死面积
  • MADM 克隆分析显示双重干预使新生心肌细胞形成增加 28%,较对照组增加超过 28 倍

关键数值与推荐

  • 双重干预后新生心肌细胞呈簇状分布比例为 28%,较对照组增加超过 28 倍
  • 时空可控的 AAV9 系统组合药物诱导 Nfyb 过表达与 CRISPR/enOsCas12f1 介导的 Nr3c1 删除

临床怎么用

  • Nfyb/Nr3c1 联合干预可作为心肌梗死后诱导心脏再生的潜在治疗方向

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Myocardial infarction can cause a massive loss of functional cardiomyocytes, yet effective strategies to stimulate cardiac regeneration remain lacking. A key barrier to adult cardiomyocyte proliferation appears to be cytokinesis inhibition. This study aimed to determine whether combining proliferation stimulators with the removal of cytokinesis-inhibitory constraints could unlock regenerative potential after myocardial infarction. METHODS: Transcriptomic profile from 5 regeneration models, including Aurkb-tdTomato cytokinesis reporter mice and Myh6-MerCreMer;mosaic analysis with double markers (MADM), and cross-species comparative analysis were used to explore the regulatory networks for cardiomyocyte proliferation. MADM mice were used to evaluate cardiac regeneration by quantifying after cytokinesis new cardiomyocytes and clonal clusters. RESULTS: Integrative multimodel analysis revealed a dual regulatory control system for cardiomyocyte proliferation, along with key associated genes and transcriptional regulators. Nfyb was identified as an activator and Nr3c1 as a repressor of cardiomyocyte proliferation. Nfyb overexpression enhanced cardiomyocyte proliferation and post-myocardial infarction cardiac repair through propelling cell-cycle gene transcription. Nr3c1 inhibition promoted cardiomyocyte proliferation, improved cardiac function, and reduced infarct size. A spatiotemporally controlled adeno-associated virus 9 system combining drug-inducible Nfyb overexpression and CRISPR/enOsCas12f1-mediated Nr3c1 deletion efficiently induces cardiomyocyte proliferation. Clonal analysis using MADM mice showed that the dual intervention synergistically increased new cardiomyocyte formation (28% clustered, >28-fold versus control). The enhanced regenerative effect of the dual intervention was demonstrated in post-myocardial infarction mice and human engineered heart tissues. CONCLUSIONS: This work documents a dual-control paradigm of cardiomyocyte proliferation and establishes Nfyb/Nr3c1 cointervention as a putative new therapy to induce and control cardiac regeneration after injury.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Lu, Liu, Ge, et al. Dual-Target Cardiac Regeneration: Controllable Nfyb/Nr3c1 Cointervention Spurs Cardiomyocyte Cytokinesis After Myocardial Infarction. Circulation. 2026. PMID: 42639656. doi:10.1161/CIRCULATIONAHA.125.079049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。